平安医药及医疗器械创新ETF(516820)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
86,729,312.28 |
-213,636,681.38 |
-322,927,964.49 |
-263,874,166.61 |
| 利息合计 |
39,291.08 |
436,819.03 |
166,933.13 |
1,739,993.84 |
| 其中：存款利息收入 |
39,291.08 |
436,819.03 |
166,933.13 |
144,397.68 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
23,981.51 |
| 投资收益合计 |
-47,201,059.56 |
-212,675,238.74 |
-112,176,022.86 |
-312,698,698.42 |
| 其中：股票投资收益 |
-60,748,556.72 |
-234,854,308.61 |
-125,902,755.06 |
-330,924,091.98 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
13,547,497.16 |
20,770,094.17 |
12,658,037.21 |
18,225,393.56 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
132,464,962.81 |
-8,407,828.30 |
-212,385,388.09 |
43,314,243.09 |
| 其他收入 |
1,426,117.95 |
7,009,566.63 |
1,466,513.33 |
3,770,294.88 |
| 费用 |
5,022,809.76 |
7,940,088.18 |
3,623,133.83 |
7,292,525.99 |
| 管理人报酬 |
4,041,040.70 |
6,319,319.00 |
2,865,387.67 |
5,768,771.66 |
| 基金托管费 |
808,208.16 |
1,263,863.75 |
573,077.50 |
1,153,754.33 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
173,560.90 |
355,000.00 |
183,988.31 |
370,000.00 |
| 利润总额 |
81,706,502.52 |
-221,576,769.56 |
-326,551,098.32 |
-271,166,692.60 |
微信公众号
证券之星APP
基本资料
